Loading stock data…
Opus Genetics, Inc. (IRD)
$4.34-0.33 (-7.07%)
Market ClosedLast close Sep 8
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Opus Genetics, Inc. in the Healthcare sector is trading at $4.34 with a market capitalization of $301M. Wall Street consensus targets $10.71 (17 analysts), implying a +146.7% move over the next 12 months. The stock is currently 25% below its 52-week high of $5.81, remaining 17.0% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. The Whystock Score of 70/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +146.7% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $2.16M↓ | $3.87M↑ | $3.08M↑ | $2.88M↓ | $4.37M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$14.36M↓ | -$11.45M↓ | -$8.31M↑ | -$8.91M↑ | -$9.93M |
| Net Income | -$65.53M↓ | -$16.52M↑ | -$17.45M↓ | -$7.42M↑ | -$8.19M |
Peer Comparison
JNJUNHPFE
Fundamentals
Opus Genetics, Inc., a clinical-stage biopharmaceutical company, develops gene therapies to restore vision and prevent blindness in patients with inherited retinal diseases (IRDs) and other types of therapies for additional ophthalmic disorders. It d...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$301.17M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.58
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
828.66%
Volume
Today's trading volume
2.26M
Recent News
Opus Genetics shares rise 5.9% ahead of OPGx-BEST1 trial data
Opus Genetics Inc (NASDAQ:IRD) shares rose 5. 9% in pre-market trading ahead of the scheduled release of three-month topline data from Cohort 1 of its OPGx-BEST1 Phase 1/2 clinical trial.
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
Opus Genetics, Inc. (NASDAQ:IRD), backed by significant analyst-implied upside, ranks among the overlooked penny stocks to buy right now. A bullish new analyst call and a broadening gene therapy pipeline are boosting confidence in the stock’s outlook. On June 23, 2026, RBC Capital initiated coverage of Opus Genetics, Inc. (NASDAQ:IRD) with an “Outperform” rating and […]
Guggenheim Initiates Coverage Of Opus Genetics (IRD) With “Buy” Rating And $16 Price Target
While Opus Genetics, Inc. (NASDAQ:IRD) has gained 100.50% year-to-date, analysts continue to see 148.10% upside, helping it secure a spot on our list of hot biotech stocks under $5 to buy. Fresh coverage initiations and a series of positive data readouts have kept analyst attention firmly on this clinical-stage gene therapy company. On June 4, […]
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within the next 12 months, President Dr. Ben Yerxa said during a fireside chat at RBC Capital Markets’ 2026